MX2010010595A - Proceso para la preparacion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihid ro-1,4-benzodioxin-2il)metil-sulfamida. - Google Patents

Proceso para la preparacion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihid ro-1,4-benzodioxin-2il)metil-sulfamida.

Info

Publication number
MX2010010595A
MX2010010595A MX2010010595A MX2010010595A MX2010010595A MX 2010010595 A MX2010010595 A MX 2010010595A MX 2010010595 A MX2010010595 A MX 2010010595A MX 2010010595 A MX2010010595 A MX 2010010595A MX 2010010595 A MX2010010595 A MX 2010010595A
Authority
MX
Mexico
Prior art keywords
preparation
sulfamates
benzo
nzodioxin
sulfamide
Prior art date
Application number
MX2010010595A
Other languages
English (en)
Inventor
Steven J Mehrman
Ahmed F Abdel-Magid
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2010010595A publication Critical patent/MX2010010595A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/04—Seven-membered rings not condensed with other rings
    • C07D321/08—1,4-Dioxepines; Hydrogenated 1,4-dioxepines

Abstract

La presente invención se dirige a un proceso para la preparación de sulfamatos de heteroarilo benzofusionado, útiles para el tratamiento de epilepsia y trastornos relacionados, de conformidad con la Fórmula (lA) y con un compuesto cristalino de la Fórmula (l-S).Proceso para la preparación de un compuesto de Fórmula (lA).
MX2010010595A 2008-03-26 2008-03-26 Proceso para la preparacion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihid ro-1,4-benzodioxin-2il)metil-sulfamida. MX2010010595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/058233 WO2009120191A1 (en) 2008-03-26 2008-03-26 Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of n- ( ( (2s) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide

Publications (1)

Publication Number Publication Date
MX2010010595A true MX2010010595A (es) 2010-10-25

Family

ID=40030223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010595A MX2010010595A (es) 2008-03-26 2008-03-26 Proceso para la preparacion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihid ro-1,4-benzodioxin-2il)metil-sulfamida.

Country Status (14)

Country Link
EP (1) EP2280950A1 (es)
JP (1) JP2011515464A (es)
KR (1) KR20100126535A (es)
CN (1) CN101981019A (es)
AU (1) AU2008353491A1 (es)
BR (1) BRPI0822454A2 (es)
CA (1) CA2719624A1 (es)
CR (1) CR11761A (es)
EA (1) EA201071120A1 (es)
EC (1) ECSP10010499A (es)
IL (1) IL208222A0 (es)
MX (1) MX2010010595A (es)
WO (1) WO2009120191A1 (es)
ZA (1) ZA201007611B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006127184A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
AU2009271362B2 (en) * 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN107954906B (zh) * 2017-11-24 2020-10-16 西北师范大学 一种芳基磺酰叔胺类化合物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AU2005277134A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
TW200738669A (en) * 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide

Also Published As

Publication number Publication date
CR11761A (es) 2011-07-06
EA201071120A1 (ru) 2011-06-30
ECSP10010499A (es) 2010-10-30
IL208222A0 (en) 2010-12-30
KR20100126535A (ko) 2010-12-01
CA2719624A1 (en) 2009-10-01
EP2280950A1 (en) 2011-02-09
BRPI0822454A2 (pt) 2015-06-16
JP2011515464A (ja) 2011-05-19
WO2009120191A1 (en) 2009-10-01
ZA201007611B (en) 2012-04-25
CN101981019A (zh) 2011-02-23
AU2008353491A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
MX2010010595A (es) Proceso para la preparacion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihid ro-1,4-benzodioxin-2il)metil-sulfamida.
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
WO2008011131A3 (en) Amide compounds
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
MY146084A (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents
MX2011007978A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
NZ597866A (en) Therapeutic lactams
MX2010009931A (es) Proceso para la preparacion de 2-amino-2-[2-(4-c3-c21-alquil-fenil )-etil]-propano-1,3-dioles.
GEP20146170B (en) Improved process for pharmaceutical compound preparation
UA102816C2 (ru) Способ синтеза кристаллической формы v агомелатина
MX2010001512A (es) Nuevo procedimiento de preparacion.
ZA200800138B (en) Process for the preparation of crystalline perindopril
IL206570A0 (en) Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use
MY179041A (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
WO2008006720A3 (en) Crystalline nemorubicin hydrochloride
JO2851B1 (en) 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof.
HK1128462A1 (en) Novel method for preparation of ammonium salts of esomeprazole
WO2012164055A3 (en) New compounds, synthesis and use thereof in the treatment of pain
MX2010003056A (es) Polimorfos de valomaciclovir.
CL2009001088A1 (es) Forma cristalina (ii) de (1r,4r)-4-(1,1-dimetiletilsulfonamido)-n-(5-(trifluorometil) piridin-2-il) ciclohexancarboxamida; procesos de preparacion; utiles como antagonistas del receptor npyy5.